Item 2.02 Results of Operations and Financial Condition

On August 8, 2022, Salarius Pharmaceuticals, Inc. (the "Company") reported financial results for the three months ended June 30, 2022 and other recent corporate updates. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 2.02 of this Current Report on 8-K (including Exhibit 99.1 hereto) is furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information shall not be deemed incorporated by reference into any other filing with the Securities and Exchange Commission made by the Company, whether made before or after today's date, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific references in such filing.

Item 9.01 Financial Statements and Exhibits.



(d) Exhibits
Exhibit No.             Description

             99.1         Press Release Announcing Financial Results, dated August 8, 2022
              104       Cover Page Interactive Data File (embedded within the inline XBRL document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses